Welcome to our dedicated page for Cue Biopharma news (Ticker: $CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cue Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cue Biopharma's position in the market.
Cue Biopharma, Inc. reported their first-quarter 2024 financial results, showcasing an increase in collaboration revenue to $1.7 million due to partnerships. They highlighted advancements in clinical trials for CUE-101 and CUE-102, as well as the expansion of their pipeline to include programs for autoimmune and inflammatory diseases. The company emphasized progress in their autoimmune program, CUE-401, with Ono Pharmaceutical, and the development of the bispecific Immuno-STAT CUE-500 series. Financially, Cue Biopharma reported $41.0 million in cash and cash equivalents as of March 31, 2024, with expectations to fund operations into the first quarter of 2025.
Cue Biopharma, Inc. (Nasdaq: CUE) is set to present at the 20th PEGS Boston Summit with two poster presentations discussing their innovative Immuno-STAT biologics for targeting autoimmune diseases and immuno-oncology. The presentations will cover the CUE-500 series for depleting B cells in autoimmune diseases and the Immuno-STAT platform for cancer and inflammatory diseases.
Cue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside chat at The Citizens JMP Life Sciences Conference in New York to discuss current oncology and autoimmune disease strategies and progress. The webcast of the chat will be available on the company's website.